A detailed history of Ubs Asset Management Americas Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 2,154,250 shares of ARWR stock, worth $45.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,154,250
Previous 2,290,154 5.93%
Holding current value
$45.3 Million
Previous $59.5 Million 29.93%
% of portfolio
0.01%
Previous 0.02%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.36 - $29.54 $2.63 Million - $4.01 Million
-135,904 Reduced 5.93%
2,154,250 $41.7 Million
Q2 2024

Aug 13, 2024

BUY
$21.87 - $28.24 $29.7 Million - $38.3 Million
1,356,254 Added 145.22%
2,290,154 $59.5 Million
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $473,290 - $686,715
-17,394 Reduced 1.83%
933,900 $26.7 Million
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $4.46 Million - $6.53 Million
210,412 Added 28.4%
951,294 $29.1 Million
Q3 2023

Nov 13, 2023

BUY
$26.2 - $36.08 $5.34 Million - $7.36 Million
203,917 Added 37.98%
740,882 $19.9 Million
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $924,561 - $1.5 Million
39,044 Added 7.84%
536,965 $13.6 Million
Q4 2022

Feb 14, 2023

BUY
$28.0 - $40.56 $11.5 Million - $16.7 Million
411,561 Added 476.56%
497,921 $20.2 Million
Q3 2022

Nov 14, 2022

SELL
$29.63 - $48.31 $692,304 - $1.13 Million
-23,365 Reduced 21.29%
86,360 $2.85 Million
Q2 2022

Aug 12, 2022

SELL
$27.79 - $50.61 $115,634 - $210,588
-4,161 Reduced 3.65%
109,725 $3.86 Million
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $664,704 - $1.17 Million
16,777 Added 17.28%
113,886 $5.24 Million
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $80,338 - $114,111
-1,383 Reduced 1.4%
97,109 $6.44 Million
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $632,313 - $920,201
10,831 Added 12.36%
98,492 $6.15 Million
Q2 2021

Aug 16, 2021

SELL
$62.15 - $90.32 $236,170 - $343,216
-3,800 Reduced 4.15%
87,661 $7.26 Million
Q1 2021

May 14, 2021

SELL
$61.35 - $90.47 $1.6 Million - $2.36 Million
-26,135 Reduced 22.22%
91,461 $6.06 Million
Q4 2020

Mar 01, 2021

BUY
$43.82 - $85.37 $502,922 - $979,791
11,477 Added 10.82%
117,596 $9.02 Million
Q3 2020

Nov 13, 2020

BUY
$33.21 - $51.27 $31,383 - $48,450
945 Added 0.9%
106,119 $4.57 Million
Q2 2020

Aug 14, 2020

BUY
$26.12 - $43.27 $425,155 - $704,305
16,277 Added 18.31%
105,174 $4.54 Million
Q1 2020

May 15, 2020

SELL
$20.56 - $63.12 $24,610 - $75,554
-1,197 Reduced 1.33%
88,897 $2.56 Million
Q4 2019

Feb 14, 2020

SELL
$28.14 - $73.01 $29,181 - $75,711
-1,037 Reduced 1.14%
90,094 $5.71 Million
Q3 2019

Nov 14, 2019

BUY
$26.26 - $34.86 $362,755 - $481,556
13,814 Added 17.87%
91,131 $2.57 Million
Q2 2019

Aug 15, 2019

BUY
$17.43 - $28.82 $629,955 - $1.04 Million
36,142 Added 87.78%
77,317 $0
Q1 2019

May 14, 2019

SELL
$12.05 - $20.18 $169,772 - $284,316
-14,089 Reduced 25.49%
41,175 $0
Q4 2018

Feb 13, 2019

SELL
$10.74 - $19.7 $128,901 - $236,439
-12,002 Reduced 17.84%
55,264 $686,000
Q3 2018

Nov 14, 2018

BUY
$14.0 - $20.3 $254,576 - $369,135
18,184 Added 37.05%
67,266 $0
Q2 2018

Aug 14, 2018

BUY
$6.37 - $14.02 $312,652 - $688,129
49,082 New
49,082 $0

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.23B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.